

## Publikationen im Modul Schizophrenie (Auswahl)

Neuhaus AH, Opgen-Rhein C, Urbanek C, Gross M, Hahn E, Ta TM, Koehler S, Dettling M. Spatiotemporal mapping of sex differences during attentional processing. *Hum Brain Mapp.* 2009 Sep;30(9):2997-3008.

Urbanek C, Neuhaus AH, Opgen-Rhein C, Strathmann S, Wieseke N, Schaub R, Hahn E, Dettling M. Attention network test (ANT) reveals gender-specific alterations of executive function in schizophrenia. *Psychiatry Res.* 2009 Jul 30;168(2):102-9.

Neuhaus AH, Opgen-Rhein C, Urbanek C, Hahn E, Ta TM, Seidelsohn M, Strathmann S, Kley F, Wieseke N, Sander T, Dettling M. COMT Val 158 Met polymorphism is associated with cognitive flexibility in a signal discrimination task in schizophrenia. *Pharmacopsychiatry.* 2009 Jul;42(4):141-4.

Neuhaus AH, Goldberg TE, Hassoun Y, Bates JA, Nassauer KW, Sevy S, Opgen-Rhein C, Malhotra AK. Acute dopamine depletion with branched chain amino acids decreases auditory top-down event-related potentials in healthy subjects. *Schizophr Res.* 2009 Jun;111(1-3):167-73.

Anghelescu I, Dettling M. Are new drugs for schizophrenia better than old ones? *Lancet.* 2009 Apr 11;373(9671):1249; author reply 1249-50.

Dettling M, Anghelescu IG. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. *N Engl J Med.* 2009 Feb 26;360(9):931.

Opgen-Rhein C, Neuhaus AH, Urbanek C, Hahn E, Sander T, Dettling M. Executive attention in schizophrenic males and the impact of COMT Val108/158Met genotype on performance on the attention network test. *Schizophr Bull.* 2008 Nov;34(6):1231-9.

Dettling M, Opgen-Rhein C, Anghelescu I. Escitalopram, problem-solving therapy, and poststroke depression. *JAMA.* 2008 Oct 15;300(15):1757.

Opgen-Rhein C, Dettling M. Clozapine-induced agranulocytosis and its genetic determinants. *Pharmacogenomics.* 2008 Aug;9(8):1101-11.

Opgen-Rhein C, Lencz T, Burdick KE, Neuhaus AH, DeRosse P, Goldberg TE, Malhotra AK. Genetic variation in the DAOA gene complex: impact on susceptibility for schizophrenia and on cognitive performance. *Schizophr Res.* 2008 Aug;103(1-3):169-77.

Dettling M, Anghelescu I, Bajbouj M. Electroconvulsive therapy for depression. *N Engl J Med.* 2008 Feb 7;358(6):645.

Rentsch J, de Castro AG, Neuhaus A, Jockers-Scherübl MC, Gallinat J. Comparison of midlatency auditory sensory gating at short and long interstimulus intervals. *Neuropsychobiology.* 2008;58(1):11-8.

Neuhaus AH, Koehler S, Opgen-Rhein C, Urbanek C, Hahn E, Dettling M. Selective anterior cingulate cortex deficit during conflict solution in schizophrenia: an event-related potential study. *J Psychiatr Res.* 2007 Oct;41(8):635-44.

Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. *Pharmacogenomics J*. 2007 Oct;7(5):325-32.

Körtner K, Neuhaus AH, Schürer F, Dettling M. Eosinophilia indicating subclinical clozapine-induced pericarditis. *J Clin Psychiatry*. 2007 Jul;68(7):1147-8.

Neuhaus AH, Luborzewski A, Opgen-Rhein C, Jockers-Scherübl MC, Neu P. Electroconvulsive monotherapy in confusion psychosis: a potential standard regimen? *Pharmacopsychiatry*. 2007 Jul;40(4):170-1.

Neuhaus AH, Luborzewski A, Rentzsch J, Brakemeier EL, Opgen-Rhein C, Gallinat J, Bajbouj M. P300 is enhanced in responders to vagus nerve stimulation for treatment of major depressive disorder. *J Affect Disord*. 2007 Jun;100(1-3):123-8.

Opgen-Rhein C, Neuhaus AH, Dettling M. Transient hyperglycemia and decreased glucose tolerance during antipsychotic monotherapy with amisulpride. *J Clin Psychopharmacol*. 2007 Feb;27(1):92-3.

Dettling M, Opgen-Rhein C, Quante A, Angheliescu I. Fluoxetine for treatment of anorexia nervosa. *JAMA*. 2006 Nov 22;296(20):2439-40; author reply 2440.

Dettling M, Opgen-Rhein C, Angheliescu IG. Homocysteine lowering and cognitive performance. *N Engl J Med*. 2006 Sep 28;355(13):1390; author reply 1391.

Neuhaus A, Bajbouj M, Kienast T, Kalus P, von Haebler D, Winterer G, Gallinat J. Persistent dysfunctional frontal lobe activation in former smokers. *Psychopharmacology (Berl)*. 2006 Jun;186(2):191-200.

Dettling M, Angheliescu IG. Antipsychotic drugs and schizophrenia. *N Engl J Med*. 2006 Jan 19;354(3):298-300.

Neuhaus AH, Katchanov J, Opgen-Rhein C, Neu P, Jockers-Scherübl MC. Electroconvulsive monotherapy in the treatment of acute confusion psychosis. A case report. *Pharmacopsychiatry*. 2005 Nov;38(6):330-2.

Mosyagin I, Cascorbi I, Schaub R, Krüger T, Dettling M. Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms? *J Clin Psychopharmacol*. 2005 Oct;25(5):435-40.

Regen F, Merkl A, Heuser I, Dettling M, Angheliescu I. [Diabetes and depression]. *Dtsch Med Wochenschr*. 2005 Apr 29;130(17):1097-102.

Angheliescu I, Urbanek C. Tadalafil in a patient with treatment-resistant depression and antidepressant polypharmacy. *J Clin Psychopharmacol*. 2005 Apr;25(2):191-2.

Reischies FM, Neuhaus AH, Hansen ML, Mientus S, Mulert C, Gallinat J. Electrophysiological and neuropsychological analysis of a delirious state: the role of the anterior cingulate gyrus. *Psychiatry Res*. 2005 Feb 28;138(2):171-81.

Neuhaus AH, Gallinat J, Bajbouj M, Reischies FM. Interictal slow-wave focus in left medial temporal lobe during bilateral electroconvulsive therapy. *Neuropsychobiology*. 2005;52(4):183-9.

Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. *J Clin Psychopharmacol*. 2004 Dec;24(6):613-7.

Neumann T, Neuner B, Gentilello LM, Weiss-Gerlach E, Mentz H, Rettig JS, Schröder T, Wauer H, Müller C, Schütz M, Mann K, Siebert G, Dettling M, Müller JM, Kox WJ, Spies CD. Gender differences in the performance of a computerized version of the alcohol use disorders identification test in subcritically injured patients who are admitted to the emergency department. *Alcohol Clin Exp Res*. 2004 Nov;28(11):1693-701.

Krüger T, Schönhoff M, Dettling M. [Neurocognition, psychosocial outcome and vocational integration]. *Psychiatr Prax*. 2004 Nov;31 Suppl 2:S224-9.

Opgen-Rhein C, Neuhaus A, Urbanek C, Dettling M. [New strategies in schizophrenia: impact of endophenotypes]. *Psychiatr Prax*. 2004 Nov;31 Suppl 2:S194-9.

Dettling M, Schönhoff M. [Social psychiatry and schizophrenia--changes and perspectives]. *Psychiatr Prax*. 2004 Nov;31 Suppl 2:S185-8.

Heuser I, Dettling M. [Health economic aspects of medical care and therapeutic options for schizophrenic and depressive patients in Germany]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2004 Aug;47(8):745-50.

Dettling M, Sander T, Weber M, Steinlein OK. Mutation analysis of the ryanodine receptor gene isoform 3 (RYS3) in recurrent neuroleptic malignant syndrome. *J Clin Psychopharmacol*. 2004 Aug;24(4):471-3.

Neu P, Seyfert S, Brockmöller J, Dettling M, Marx P. Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency. *Pharmacopsychiatry*. 2002 Jan;35(1):26-8.

Kaiser R, Tremblay PB, Schmider J, Henneken M, Dettling M, Müller-Oerlinghausen B, Uebelhack R, Roots I, Brockmöller J. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparoid and residual subtypes of schizophrenia. *Mol Psychiatry*. 2001 Mar;6(2):179-85.

Dettling M, Schaub RT, Mueller-Oerlinghausen B, Roots I, Cascorbi I. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. *Pharmacogenetics*. 2001 Mar;11(2):135-41.

Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. *Arch Gen Psychiatry*. 2001 Jan;58(1):93-4.

Dettling M, Sachse C, Müller-Oerlinghausen B, Roots I, Brockmüller J, Rolf A, Cascorbi I. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. *Pharmacopsychiatry*. 2000 Nov;33(6):218-20.

Dettling M, Sachse C, Brockmüller J, Schley J, Müller-Oerlinghausen B, Pickersgill I, Rolf A, Schaub RT, Schmider J. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. *Psychopharmacology (Berl)*. 2000 Sep;152(1):80-6.

Kaiser R, Könniker M, Henneken M, Dettling M, Müller-Oerlinghausen B, Roots I, Brockmüller J. Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. *Mol Psychiatry*. 2000 Jul;5(4):418-24.

Sachse C, Ruschen S, Dettling M, Schley J, Bauer S, Müller-Oerlinghausen B, Roots I, Brockmüller J. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. *Clin Pharmacol Ther*. 1999 Oct;66(4):431-8.

Dettling M, Cascorbi I, Hellweg R, Deicke U, Weise L, Müller-Oerlinghausen B. Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine? *Pharmacopsychiatry*. 1999 May;32(3):110-2.

Dettling M, Müller-Oerlinghausen B, Britsch P. Clozapine treatment of HIV-associated psychosis--too much bone marrow toxicity? *Pharmacopsychiatry*. 1998 Jul;31(4):156-7.